Niazoxanide derivative and medical application thereof

By reacting nitazolinide derivatives with pyridinyl chloride, the problem of high dose of nitazolinide in diabetes model was solved, and its pharmacological activity was improved. It was used to prepare antiviral and hypoglycemic drugs, achieving safe doses higher efficacy.

CN118978524APending Publication Date: 2024-11-19SHAOXING JUNKE ZHENYUAN PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410391334.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2019-09-11
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Nitazonidone is a high effective dose of hypoglycemic in a diabetic rat model induced by high fat/strand zotomycin, which is much larger than its clinically safe dose, resulting in improved efficacy becoming a bottleneck restricting its new uses.

Method used

By reacting the derivative of nitazolinide with pyridinyl chloride, a new nitazolinide derivative is prepared to improve its pharmacological activity and is used to prepare drugs for antiviral, antihepatitis B virus, lowering glycemic and treating metabolic diseases.

Benefits of technology

It significantly reduces the effective dose of nitazonid, improves its therapeutic effect on a variety of viral and metabolic diseases, enhances its pharmacological activity, and achieves higher efficacy under safe doses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978524A_ABST
    Figure CN118978524A_ABST
Patent Text Reader

Abstract

The invention relates to a novel nitazoxanide derivative represented by a formula I: # imgabs0 #, in which R is H, CH3, C1 or F and is connected to any position on a benzene ring; and X is NO2, Cl or Br.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts and hydrates. Background Art

[0002] Nitazoxanide (chemical name: o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-acetate) is a nitrothiazole salicylic acid amide with antiprotozoal, anti-intestinal parasite, and antibacterial effects, and its antiparasitic and antibacterial spectra are broader than those of albendazole and metronidazole.

[0003]

[0004] Further studies have found that nitazoxanide and its analogs such as RM-5038 also have broad-spectrum antiviral activity, and have inhibitory effects on a variety of respiratory viruses, hepatitis C virus and hepatitis B virus.

[0005] Nitazoxanide also has good anti-tumor activity. Recent research results show that nitazoxanide also has a certain hypoglycemic effect. These research results bring new uses for nitazoxanide.

[0006] However, like most old drugs with new use prospects, the activity of these new pharmacological effects of nitazoxanide needs to be improved. For example, in a high-fat / streptozotocin-induced diabetic rat model, its effective glucose-lowering dose is as high as 200 mg / kg (Samah M. Elaidy, et al. Can. J. Physiol. Pharmacol. 2008; 96: 485-497.), which is equivalent to 1944 mg for an adult (weight 60 kg), which is much larger than the clinical safe dose of nitazoxanide (500 mg / time).

[0007] Therefore, how to improve the efficacy of old drugs has become a bottleneck restricting their new medicinal uses. Summary of the invention

[0008] The object of the present invention is to provide novel nitazoxanide derivatives represented by formula I:

[0009]

[0010] Wherein, R is H, CH3, Cl or F, which is connected to any position on the benzene ring; X is NO2, Cl or Br.

[0011] The present invention also provides non-toxic pharmaceutically acceptable salts of the novel nitazoxanide derivatives represented by formula I.

[0012] The present invention also provides a pharmaceutical composition comprising the novel nitazoxanide derivative represented by formula I and its non-toxic pharmaceutically acceptable salt as an active ingredient.

[0013] The present invention also provides novel nitazoxanide derivatives represented by formula I and their non-toxic pharmaceutically acceptable salts, as well as pharmaceutical compositions containing the novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as active ingredients, and their use in preparing antiviral drugs.

[0014] The present invention also provides novel nitazoxanide derivatives represented by formula I and their non-toxic pharmaceutically acceptable salts, as well as pharmaceutical compositions containing the novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as active ingredients, and their use in preparing anti-hepatitis B virus drugs.

[0015] The present invention also provides novel nitazoxanide derivatives represented by formula I and their non-toxic pharmaceutically acceptable salts, as well as pharmaceutical compositions containing the novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as active ingredients, and their use in preparing drugs for treating metabolic diseases.

[0016] The present invention also provides novel nitazoxanide derivatives represented by formula I and their non-toxic pharmaceutically acceptable salts, as well as pharmaceutical compositions containing the novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as active ingredients, and their use in preparing hypoglycemic drugs.

[0017] The present invention also provides novel nitazoxanide derivatives represented by formula I and their non-toxic pharmaceutically acceptable salts, as well as pharmaceutical compositions containing the novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as active ingredients, and their use in preparing drugs for treating non-alcoholic fatty hepatitis. DETAILED DESCRIPTION

[0018] The present invention can be further described with reference to the following examples; however, these examples should not be construed as limiting the scope of the present invention.

[0019] Taking the derivatives of nitazoxanide as an example, the target compound of the present invention can be prepared according to the following synthetic route:

[0020]

[0021] The nitazoxanide is hydrolyzed to obtain deacetyl nitazoxanide; the deacetyl nitazoxanide is reacted with pyridinecarbonyl chloride to obtain the target compound.

[0022] Reference Example 1 Preparation of 2-hydroxybenzoic acid-N-(5-chlorothiazol-2-yl)amide (RM-4848) The preparation was carried out according to the literature (J Med Chem. 2011; 54(12): 4119-4132.), and the synthetic route is as follows:

[0023]

[0024] In 500 ml of anhydrous ether, add 18 g of acetylsalicylic acid and 9.5 g of pyridine, cool to 0°C in an ice bath, and add 14.3 g of thionyl chloride dropwise with stirring; after the addition, continue stirring at 0°C for 4 hours, filter, and evaporate the filtrate to dryness under reduced pressure to obtain acetylsalicylic acid chloride, which is directly used in the next reaction.

[0025] Add 33.6g NaHCO3 and 500ml ethyl acetate to 500ml water, and add 17.1g 2-amino-5-chlorothiazole hydrochloride under vigorous stirring. Add a solution of acetylsalicylic acid chloride in 100ml ethyl acetate dropwise under vigorous stirring, and stir the reaction mixture at room temperature for 12 hours. Separate the organic layer, extract the water layer with ethyl acetate; combine the ethyl acetate extracts, wash with 0.5N hydrochloric acid twice and saturated brine once. Dry, evaporate to dryness under reduced pressure, separate by silica gel column chromatography, elute with ethyl acetate-n-hexane (1:1), collect the desired eluted components, evaporate to dryness under reduced pressure, and obtain RM-503827.8g.

[0026] Add 25g RM-5038 to 200ml concentrated hydrochloric acid, stir and disperse at room temperature; heat the system to 50℃ and stir to react for about 15 hours. Cool to room temperature, filter, and wash the filter cake with 50ml×3 times of purified water. Drain dry, and air dry the filter cake at 60℃ for 12 hours to obtain RM-484819.2g. Nuclear magnetic resonance hydrogen spectrum (ppm, DMSO-d6): 7.00 (1H, t); 7.04 (1H, d), 7.48 (1H, t); 7.60 (1H, s); 7.96 (1H, d).

[0027] Example 1 Preparation of o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-pyridine-3-carboxylate (I-1)

[0028]

[0029] Example 1.1 Synthesis of deacetyl nitazoxanide

[0030] Take 30.00 g of nitazoxanide, add it to a 250 ml single-mouth bottle, add 180 ml of concentrated hydrochloric acid, stir and disperse at room temperature; heat the system to 50°C and stir and react for about 15 hours. After the reaction, cool the reaction system to room temperature, filter, and wash the filter cake with 50 ml × 3 times of purified water. Drain dry, and air dry the filter cake at 60°C for 12 hours to obtain 21.1 g of light yellow solid deacetyl nitazoxanide.

[0031] Example 1.2 Synthesis of o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-pyridine-3-carboxylate (I-1)

[0032] Under argon protection, add 3.0g of deacetyl nitazoxanide to 75ml of tetrahydrofuran solvent, add 5.6g of triethylamine under stirring, and stir to dissolve until clear; cool to 0°C in an ice bath, add 5.8g of pyridine-3-carbonyl chloride hydrochloride in batches under stirring, stir for 0.5 hours under ice bath and argon protection after adding, and then react at room temperature for 15 hours. Filter to remove insoluble matter, wash the filter cake with 5ml of tetrahydrofuran, combine the washing filtrate, and evaporate to dryness under reduced pressure. Separate the residue by silica gel column chromatography, elute with dichloromethane / methanol (10 / 1), collect the desired components, and evaporate to dryness under reduced pressure to obtain 2.3g of I-1. H NMR (ppm, DMSO-d6): 9.25 (d, 1H); 8.89-8.91 (m, 1H); 8.65 (s, 1H); 8.43-8.46 (m, 1H); 7.94-7.96 (m, 1H); 7.74-7.79 (m, 1H); 7.64-7.66 (m, 1H); 7.51-7.55 (m, 1H); 7.51-7.55 (m, 1H).

[0033] Example 2 Preparation of o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-pyridine-2-carboxylate (I-2)

[0034]

[0035] Referring to the method of Example 1.2, pyridine-2-carbonyl chloride hydrochloride was used instead of pyridine-3-carbonyl chloride hydrochloride to react with deacetyl nitazoxanide; the reaction product was separated by silica gel column chromatography to obtain 1.7 g of I-2. H NMR (ppm, DMSO-d6): 9.23 (d, 1H); 8.85-8.89 (m, 1H); 8.64 (s, 1H); 8.33-8.36 (m, 1H); 7.97-7.99 (m, 1H); 7.76-7.80 (m, 2H); 7.63-7.65 (m, 1H); 7.50-7.54 (m, 1H).

[0036] Example 3 Preparation of o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-pyridine-4-carboxylate (I-3)

[0037]

[0038] Referring to the method of Example 1.2, pyridine-4-carbonyl chloride hydrochloride was used instead of pyridine-3-carbonyl chloride hydrochloride to react with deacetyl nitazoxanide; the reaction product was separated by silica gel column chromatography to obtain 1.9 g of I-3. H NMR (ppm, DMSO-d6): 9.22 (d, 1H); 8.90-8.92 (d, 2H); 8.63 (s, 1H); 7.95-7.97 (d, 2H); 7.73-7.78 (m, 1H); 7.62-7.64 (m, 1H); 7.49-7.53 (m, 1H).

[0039] Example 4 Preparation of o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-pyridine-3-carboxylate (I-4)

[0040]

[0041] Referring to the method of Example 1.2, RM-4848 was used instead of deacetyl nitazoxanide to react with pyridine-3-carbonyl chloride; the reaction product was separated by silica gel column chromatography to obtain 2.2 g of I-4. H NMR (ppm, DMSO-d6): 9.20 (d, 1H); 8.88-8.90 (m, 1H); 8.42-8.45 (dt, 1H); 7.93-7.95 (m, 1H); 7.59 (1H, s); 7.71-7.76 (m, 1H); 7.60-7.62 (m, 1H); 7.50-7.54 (m, 2H).

[0042] Example 5 Preparation of o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-pyridine-2-carboxylate (I-5)

[0043]

[0044] Referring to the method of Example 1.2, RM-4848 was used instead of deacetyl nitazoxanide to react with pyridine-2-carbonyl chloride; the reaction product was separated by silica gel column chromatography to obtain 2.0 g of I-5. H NMR (ppm, DMSO-d6): 9.21 (d, 1H); 8.82-8.86 (m, 1H); 8.31-8.34 (m, 1H); 7.96-7.98 (m, 1H); 7.76-7.80 (m, 2H); 7.56 (1H, s); 7.63-7.65 (m, 1H); 7.49-7.53 (m, 1H).

[0045] Example 6 Preparation of o-N-(5-nitrothiazol-2-yl)carbamoyl-phenol-pyridine-4-carboxylate (I-6)

[0046]

[0047] Referring to the method of Example 1.2, RN-4848 was used instead of deacetyl nitazoxanide to react with pyridine-4-carbonyl chloride; the reaction product was separated by silica gel column chromatography to obtain 1.7 g of I-6. H NMR (ppm, DMSO-d6): 9.24 (d, 1H); 8.90-8.92 (d, 2H); 8.61 (s, 1H); 7.95-7.97 (d, 2H); 7.72-7.77 (m, 1H); 7.63-7.65 (m, 1H); 7.49-7.53 (m, 1H).

[0048] Example 7 Determination of in vitro anti-HBV activity and cytotoxicity

[0049] Example 7.1 Determination of cytotoxicity

[0050] Hep G 2.2.15 cells were cultured in DMEM containing 10% calf serum and seeded in 96-well plates at a cell count of 3 × 10 4 / well, incubate in a 5% CO2 incubator. When the cell density reaches 80%, discard the old culture medium and add new culture medium containing different concentrations of the drug to be tested, 200μl / well, set up 3 parallel wells; replace the culture medium every 2 days. On the 10th day after administration, add 7.5mg / ml MIT, 30μl / well, continue to culture for 3 hours, discard the supernatant, add acidic isopropanol solution containing 10% Tween X-100, 120μl / well, measure the absorption at 540nm with an enzyme-linked analyzer, and calculate the 50% inhibition concentration, which is CC 50 value.

[0051] Example 7.2 Determination of anti-HBV activity

[0052] Hep G 2.2.15 cells were cultured in DMEM containing 10% calf serum and seeded in 96-well plates at a cell count of 3 × 10 4 / well, incubate in a 5% CO2 incubator. When the cell density reaches 80%, discard the old culture medium and add new culture medium containing different concentrations of the drug to be tested, 200μl / well, set up 3 parallel wells; replace the culture medium every 2 days. On the 10th day after administration, take 100μl of supernatant and determine the HBV DNA content by quantitative PCR. Calculate the 50% inhibition concentration, which is IC 50 value.

[0053] The experimental results are shown in Table 1:

[0054] Table 1 In vitro anti-HBV activity and cytotoxicity

[0055]

[0056] Example 8 Evaluation of in vivo anti-HBV effect

[0057] Ducks with vertically transmitted infection and positive DHBV DNA were randomly divided into 8 groups. Nitazoxanide, RM-5038 and different doses of the test compound were prepared into suspensions with 0.1% sodium carboxymethyl cellulose and administered orally once a day. 14 days), 21 days of medication (T 21 days) and 28 days (T 28 Blood was collected from the vein on the day of the experiment, and serum was separated and stored at -70℃ for testing.

[0058] Determination of DHBV DNA level in serum by dot hybridization: Take the above duck serum and spot each batch of membrane at the same time to determine the change of DHBV DNA level in duck serum. 32 P-labeled DHBV DNA probe was used for duck serum dot blot experiment. After autoradiography, the spectral absorbance of the spots on the autoradiography X-ray film was measured by enzyme-linked immunosorbent assay (filter wavelength was 490 nm). 490 , O.D. 490 The higher the value, the higher the virus level.

[0059] The measurement results are shown in Table 2:

[0060] Table 2. Evaluation results of in vivo anti-duck hepatitis B virus effect

[0061]

[0062] Note: Comparison of drug group at different administration time with before administration (T0): **P<0.01 *P<0.05 Comparison of drug group with control group at the same time: ΔΔP<0.01 ΔP<0.05 Example 9 Evaluation of hypoglycemic and hypolipidemic effects of target compounds using db / db mouse model

[0063] 60 9-10 week old db / db mice and 8 C57 wild control mice were acclimated to the environment and raised for 13 days. The 4h fasting blood glucose value of db / db mice was tested and randomly divided into groups according to body weight and blood glucose value (G1: normal group, C57 mice; G2: solvent group; G3: I1100mg / kg; G4: I1200mg / kg; G5: nitazoxanide 200mg / kg; G6: nitazoxanide 200mg / kg + pyridine-3-carboxylic acid 80mg / kg); nitazoxanide, RM--5038 and different doses of the test compound were prepared into a suspension with 0.1% sodium carboxymethyl cellulose and administered by gavage once a day. On the 14th day of administration, the mice were fasted for 4h, then given the test drug, and blood glucose was tested by tail tip blood sampling 1h later. The test results are shown in Table 3.

[0064] OGTT assay: On the 15th day, the animals were fasted for 16 hours overnight. The animals were weighed on the second day, and the blood glucose at 0 min was measured with a blood glucose meter. Glucose solution (2 g / kg) was immediately administered by oral gavage while the test substance was administered, and the blood glucose values ​​were measured at 30 min, 60 min, 120 min and 180 min after administration. The area under the blood glucose time curve AUC was calculated. The results are shown in Table 4.

[0065] Table 3. Evaluation results of hypoglycemic effect in vivo

[0066]

[0067] *p<0.05, **p<0.01, ***p<0.001vs.Vehicle

[0068] Table 4. Evaluation results of glucose tolerance

[0069]

[0070] *p<0.05, ***p<0.01, ***p<0.001vs.Vehicle

[0071] Example 10 Pharmacodynamic Evaluation of Nonalcoholic Fatty Hepatitis

[0072] References (Xu Chang, Liu Zezhou, Xu Kejia, et al. Comparison of animal models of non-alcoholic fatty liver disease induced by high-fat and MCD diets. Progress in Modern Biomedicine, 2014; 14(18): 3451-3455)

[0073] C57BL / 6 mice were fed with ordinary maintenance diet for 1 week and then randomly divided into groups (G1: normal group; G2: solvent group; G3: I1 100 mg / kg; G4: I1 200 mg / kg; G5: nitazoxanide 200 mg / kg; G6: nitazoxanide 200 mg / kg + pyridine-3-carboxylic acid 80 mg / kg). The normal control group was fed with MCS diet; the other groups were fed with MCD diet, and free access to food and water for 4 weeks. After 4 weeks, a certain dose of drug or solvent control was given by gavage once a day, and the anti-NASH effect was measured at the third week after administration. Before the measurement, the mice were fasted for 12 hours after the last administration, weighed and anesthetized, the eyeballs were removed and blood was collected, and the liver tissue was fixed with paraformaldehyde to make paraffin sections and OCT to make frozen sections.

[0074] Liver tissue pathology examination: routine paraffin embedding, paraffin sectioning and HE staining, light microscopy observation and filming; frozen section routine Oil Red O staining, light microscopy observation and filming. NASH pathological diagnosis criteria are evaluated using the NAFLD Activity Score (NAS). The semi-quantitative evaluation score is shown in the following table:

[0075]

[0076] The evaluation results are shown in Table 5:

[0077] Compound NAS G1 1.02±0.1 G2 8.20±3.27 G3 2.50±1.07 G4 3.20±1.27 G5 4.21±1.55 G6 3.42±1.26

Claims

1. The new nitazoxanide derivative represented by formula I: in, R is H, CH3, Cl or F, which is connected to any position on the benzene ring; X is NO2, Cl or Br.

2. According to claim 1, the new nitazoxanide derivative represented by formula I: in, R is H, CH3, Cl or F, which is connected to any position on the benzene ring; X is NO2.

3. According to claim 1, the new nitazoxanide derivative represented by formula I: in, R is H, CH3, Cl or F, which is attached to any position on the benzene ring; X is Cl.

4. The compound of claim 1, selected from the following structures:

5. A pharmaceutical composition comprising the novel nitazoxanide derivatives and non-toxic pharmaceutically acceptable salts thereof as claimed in claims 1 to 4 as active ingredients.

6. Use of the novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as claimed in claims 1 to 4, and pharmaceutical compositions containing the nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as active ingredients in the preparation of hypoglycemic drugs.

7. Use of the novel nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as claimed in claims 1 to 4, and pharmaceutical compositions containing the nitazoxanide derivatives and their non-toxic pharmaceutically acceptable salts as active ingredients in the preparation of drugs for treating non-alcoholic steatohepatitis.